• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24040 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2010     HAYES, Inc. Velcade (Bortezomib) (Millennium: The Takeda Oncology Company) for mantle cell lymphoma
2014     NIHR Horizon Scanning Centre (NIHR HSC) Velcalcetide for secondary hyperparathyroidism – first line
2012     NIHR Horizon Scanning Centre (NIHR HSC) Velimogene aliplasmid (Allovectin) for advanced or metastatic malignant melanoma
2016     NIHR Horizon Scanning Centre (NIHR HSC) Veliparib with carboplatin and paclitaxel for early-stage triple negative breast cancer ─ neoadjuvant therapy
2023     National Institute for Health and Care Excellence (NICE) Velmanase alfa for treating alpha-mannosidosis. NICE highly specialised technologies guidance 29
2010     Adelaide Health Technology Assessment (AHTA) Velscope for oral cancer screening
2008     Adelaide Health Technology Assessment (AHTA) Velscope(R) for oral cancer screening
2015     NIHR Horizon Scanning Centre (NIHR HSC) Vemurafenib (Zelboraf) for metastatic BRAF V600 mutation positive melanoma in children and adolescents
2014     NIHR Horizon Scanning Centre (NIHR HSC) Vemurafenib and cobimetinib for previously untreated BRAFV600-mutation positive, unresectable, locally advanced or metastatic melanoma – first line
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Vemurafenib for the 1st –line unresectable stage IIIC or IV melanoma
2012     NIHR Health Technology Assessment programme Vemurafenib for the treatment of locally advanced or metastatic BRAF V600E mutation positive malignant melanoma
2012     National Institute for Health and Care Excellence (NICE) Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma. NICE technology appraisal guidance 269
2016     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) Venetoclax (Venclexta™) for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) with chromosome 17p deletion
2015     NIHR Horizon Scanning Centre (NIHR HSC) Venetoclax for chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
2022     National Institute for Health and Care Excellence (NICE) Venetoclax for treating chronic lymphocytic leukaemia. NICE technology appraisal guidance 796
2022     National Institute for Health and Care Excellence (NICE) Venetoclax with azacitidine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable. NICE technology appraisal guidance 765
2022     National Institute for Health and Care Excellence (NICE) Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable. NICE technology appraisal guidance 787
2020     National Institute for Health and Care Excellence (NICE) Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia. NICE technology appraisal guidance 663
2019     National Institute for Health and Care Excellence (NICE) Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia. NICE technology appraisal guidance 561
2016     NIHR Horizon Scanning Centre (NIHR HSC) Venetoclax with rituximab for relapsed or refractory chronic lymphocytic leukaemia – second and subsequent line
2021     NIHR Health Technology Assessment programme Venous access devices for the delivery of long-term chemotherapy: the CAVA three-arm RCT
2021     Penn Medicine Center for Evidence-based Practice (CEP) Venous irritation resulting from IV fosaprepitant
2018     Penn Medicine Center for Evidence-based Practice (CEP) Venous Thromboembolism Prevention for Obese Patients
2009     Penn Medicine Center for Evidence-based Practice (CEP) Venous thromboembolism prophylaxis for bariatric surgery
2007     Penn Medicine Center for Evidence-based Practice (CEP) Venous thromboembolism prophylaxis for hip fracture patients
2007     Penn Medicine Center for Evidence-based Practice (CEP) Venous thromboembolism prophylaxis for ischemic stroke
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Venous thromboembolism prophylaxis for major general surgery: a review of the clinical effectiveness and guidelines
2007     Penn Medicine Center for Evidence-based Practice (CEP) Venous thromboembolism prophylaxis for medical inpatients
2012     Agency for Healthcare Research and Quality (AHRQ) Venous thromboembolism prophylaxis in orthopedic surgery
2001     Norwegian Knowledge Centre for the Health Services (NOKC) Ventilation in operating theatres
2013     New Zealand National Health Committee (NHC) Ventilation tubes: an opportunity for better targeting - technology note
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) Ventilation/perfusion scintigraphy (using Technegas) versus computed tomography pulmonary angiography for the diagnosis of pulmonary embolism in hospitalized patients: a review of the clinical and cost-effectiveness
2021     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Ventral rectopexy for the treatment of rectal prolapse and intussusception
2005     HAYES, Inc. Ventricular assist devices
2003     HAYES, Inc. Ventricular assist devices
2010     HAYES, Inc. Ventricular Assist Devices (VADs) in children and adolescents with chronic, end-stage heart failure
1997     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) Ventricular assistance devices as mechanical bridge to cardiac transplantation (internal report) IPE-97/f
2003     HAYES, Inc. Ventricular reduction surgery
2004     NIHR Health Technology Assessment programme VenUS I: a randomised controlled trial of two types of bandage for treating venous leg ulcers
2009     NIHR Health Technology Assessment programme VenUS II: a randomised controlled trial of larval therapy in the management of leg ulcers
2011     NIHR Health Technology Assessment programme VenUS III: a randomised controlled trial of therapeutic ultrasound in the management of venous leg ulcers
2014     NIHR Health Technology Assessment programme VenUS IV (Venous leg Ulcer Study IV) - compression hosiery compared with compression bandaging in the treatment of venous leg ulcers: a randomised controlled trial, mixed-treatment comparison and decision-analytic model
2016     NIHR Horizon Scanning Centre (NIHR HSC) Vepoloxamer for vaso-occlusive crises in sickle cell disease – first line
2016     HAYES, Inc. Verasense (OrthoSensor Inc.) for use during total knee arthroplasty
2010     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Veress needle laparoscopic entry technique
2021     National Institute for Health and Care Excellence (NICE) Vericiguat for treating chronic heart failure with reduced ejection fraction (terminated appraisal). NICE technology appraisal guidance 731
2016     HAYES, Inc. VeriStrat
2014     HAYES, Inc. VeriStrat test to predict response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC)
2012     HAYES, Inc. VeriStrat® Test to predict response to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Non-Small Cell Lung Cancer (NSCLC)
2010     NIHR Horizon Scanning Centre (NIHR HSC) Vernakalant (IV) (Brinavess) for the treatment of recent onset atrial fibrillation
2021     National Institute for Health and Care Excellence (NICE) Vernakalant for the rapid conversion of recent onset atrial fibrillation to sinus rhythm (terminated appraisal). NICE technology appraisal guidance 675
2011     HAYES, Inc. VersaJet hydrosurgery system (Smith&Nephew Inc.) for treatment of burns
2021     Malaysian Health Technology Assessment (MaHTAS) Versajet hydrosurgery system for wound debridement: an update
2013     HAYES, Inc. VersaJet II hydrosurgery system (Smith & Nephew Inc.) for treatment of burns
2012     HAYES, Inc. VersaJet II hydrosurgery system (Smith & Nephew Inc.) for treatment of burns
2019     NIHR Health Technology Assessment programme Vertebral artery stenting to prevent recurrent stroke in symptomatic vertebral artery stenosis: the VIST RCT
2004     Blue Cross Blue Shield Association (BCBS) Vertebral assessment using dual-energy x-ray absorptiometry for osteoporotic fracture risk assessment
2007     Adelaide Health Technology Assessment (AHTA) Vertebral assessment with DEXA
2006     Adelaide Health Technology Assessment (AHTA) Vertebral assessment with DEXA: Screening for vertebral fracture during risk assessment for osteoporosis
2016     Health Quality Ontario (HQO) Vertebral augmentation involving vertebroplasty or kyphoplasty for cancer-related vertebral compression fractures: a systematic review
2016     Health Quality Ontario (HQO) Vertebral augmentation involving vertebroplasty or kyphoplasty for cancer-related vertebral compression fractures: an economic analysis
2016     Health Quality Ontario (HQO) Vertebral augmentation involving vertebroplasty or kyphoplasty for cancer-related vertebral compression fractures: OHTAC recommendation
2005     WorkSafeBC Vertebral axial decompression for low back pain
2001     Medical Services Advisory Committee (MSAC) Vertebral axial decompression therapy for chronic low back pain
2022     National Institute for Health and Care Excellence (NICE) Vertebral body tethering for idiopathic scoliosis in children and young people. NICE interventional procedures guidance 728
1999     Alberta Heritage Foundation for Medical Research (AHFMR) Vertebroplasty
2004     Institute for Clinical Systems Improvement (ICSI) Vertebroplasty and balloon-assisted vertebroplasty for the treatment of osteoporotic compression fractures
2005     Adelaide Health Technology Assessment (AHTA) Vertebroplasty and kyphoplasty for the treatment of vertebral compression fracture
2017     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vertebroplasty for severely painful osteoporotic vertebral fractures of less than 6 weeks duration
2021     Swiss Federal Office of Public Health (FOPH) Vertebroplasty or kyphoplasty in painful osteoporotic vertebral compression fractures unresponsive to non-surgical treatment
2020     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vertebroplasty or kyphoplasty in patients with symptomatic osteoporotic vertebral compression fractures unresponsive to non-surgical treatment
2020     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) Vertebroplasty or kyphoplasty in patients with symptomatic osteoporotic vertebral compression fractures unresponsive to non-surgical treatment [HTA scoping report protocol]
2012     NIHR Health Technology Assessment programme Verteporfin photodynamic therapy for neovascular age-related macular degeneration: cohort study for the UK
2006     HAYES, Inc. Vertical expandable prosthetic titanium rib (VEPTR) (Synthes Inc.) for percutaneous neuromodulation therapy for low back pain
2006     HAYES, Inc. Vertical expandable prosthetic titanium rib (VEPTR) (Synthes Inc.) for thoracic insufficiency syndrome
2023     NIHR Health Services and Delivery Research programme Vertical integration of general practices with acute hospitals in England: rapid impact evaluation
2010     Penn Medicine Center for Evidence-based Practice (CEP) Vertos mild for lumbar decompression
2011     NIHR Horizon Scanning Centre (NIHR HSC) VERV patient managed transdermal neuromodulation system for overactive bladder syndrome
1991     L'Agence Nationale d'Accreditation d'Evaluation en Sante (ANAES) Vesicular Lithiasis: therapeutic strategy for gallbladder - consensus conference
2003     ECRI Vestibular rehabilitation and particle repositioning for benign positional vertigo
2008     HAYES, Inc. Vestibulectomy for treatment of vulvar vestibulitis
2000     The Swedish Council on Health Technology Assessment (SBU) Viagra for impotence - early assessment briefs (ALERT)
2024     National Institute for Health and Care Excellence (NICE) Vibegron for treating symptoms of overactive bladder syndrome. NICE technology appraisal guidance 999
2014     National Institute for Health and Care Excellence (NICE) VibraTip for testing vibration perception to detect diabetic peripheral neuropathy. NICE medical technologies guidance 22
2022     Penn Medicine Center for Evidence-based Practice (CEP) Video camera-assisted or electromagnetic placement of enteral feeding tubes
2019     Agency for Care Effectiveness (ACE) Video capsule endoscopy for diagnosing obscure gastrointestinal bleeding
2012     Technology Assessment Unit of the McGill University Health Centre (MUHC) Video capsule endoscopy for obscure GI bleeding and Crohn's disease (Update of Report 7)
2013     HAYES, Inc. Video Electrencephalogram (VEEG) for the diagnosis and treatment of epilepsy in children
2013     HAYES, Inc. Video Electroencephalogram (VEEG) for diagnosis and management of epilepsy in adults
2007     HAYES, Inc. Video electroencephalograph (VEEG) monitoring for diagnosis of epilepsy in children
2024     Health Technology Wales (HTW) Video feedback interventions to improve communication within family relationships and support children at risk
2022     Health Technology Wales (HTW) Video laryngoscopes for use in pre-hospital care
2004     Medical Advisory Secretariat (MAS) Video laryngoscopy for tracheal intubation: an evidence-based analysis
2008     Belgian Health Care Knowledge Centre (KCE) Video registration of endoscopic surgery: a rapid assessment
2015     Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S) ViewRay System for MRI guided radiotherapy
2023     NIHR Health Technology Assessment programme Views of female genital mutilation survivors, men and health-care professionals on timing of deinfibulation surgery and NHS service provision: qualitative FGM Sister Study
2006     Canadian Agency for Drugs and Technologies in Health (CADTH) Vildagliptin
2013     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Vildagliptin (Galvus®) 50 mg tablets
2012     All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG) Vildagliptin (Galvus®) 50 mg tablets
2015     NIHR Horizon Scanning Centre (NIHR HSC) Vincristine liposomal (Marqibo) for relapsed or refractory acute lymphoblastic leukaemia – third line